Nautilus Biotechnology (NAUT) Insider B, Buys 45,000 Shares

Epperly Melissa B, made a notable move by purchasing 45,000 shares of NAUT on June 18, 2026. This insider transaction did not occur under a planned trading program.

Insider Buying and Selling at Nautilus Biotechnology, Inc.

On June 18, 2026, several insiders, including Epperly Melissa B,, Matthew McIlwain, Matthew Posard, Karen Akinsanya, Farzad Nazem, and Sujal Patel, increased their holdings in NAUT. Each of these insiders, except for Patel, acquired 45,000 shares. Sujal Patel, who serves as the CEO, President, and Secretary, bought 25,000 shares earlier on March 4, 2026, at an average price of $2.61.

Other Institutional Activity in NAUT

Several institutional investors have shown interest in NAUT. A16Z Capital Management, L.L.C. holds 17,653,917 shares valued at approximately $68.5 million. Perceptive Advisors LLC maintains its position with 12,594,211 shares worth about $48.9 million. Similarly, Cercano Management LLC holds 7,172,985 shares valued at $27.8 million. Meanwhile, Vanguard Capital Management LLC and Clearstead Advisors, LLC have both opened new positions, holding 2,545,597 and 2,329,784 shares, respectively.

Analysts Set New Price Targets

On February 27, 2026, Guggenheim maintained its 'buy' rating for NAUT, setting a price target of $4.00. Previously, on December 8, 2024, Goldman Sachs downgraded the stock to a 'sell' with a target of $1.75. Morgan Stanley has maintained a 'hold' rating with a price target of $5.00 since July 31, 2024.

Bottom Line

The recent insider buying activity at NAUT, including significant purchases by several executives, suggests confidence in the company's future. Investors often track such transactions for potential insights, though they are backward-looking and may not reflect current positions. Analyst ratings also offer varied perspectives, with Guggenheim's optimistic outlook contrasting with Goldman Sachs' more cautious stance.